Elevance Health Says 2026 One-Time Investments Will Build Durable Capabilities

Management views on “one-time investments” to accelerate capabilities (Elevance Health, ELV)

Management characterized the “one-time, non-recurring” investment spending as a 2026-only acceleration lever intended to build durable capabilities that improve long-term medical cost management and operational performance, rather than as incremental recurring expenses. ¹

1) How management described the investments (what they are meant to do)

Management emphasized that these investments are long-term, durable capabilities even though the cost is one-time/non-recurring. ¹ They said the investments are aimed at improving internal business capabilities across key levers including medical cost management, provider connectivity, and operating efficiency. ¹²

Specifically, management tied the investments to:

• Strengthening medical costs by improving analytics and enabling faster identification and action against medical cost pressures (moving “months of identification to days and hours”). ¹
• Simplifying the member experience and improving access/support via digital/member engagement efforts. ¹³
• Improving provider connectivity (e.g., Health OS tools) to reduce documentation requests, improve prior authorization, reach 80% real-time, improve payment accuracy, and reduce friction. ⁴
• Scaling value-based solutions through Carelon, including accelerating CareBridge deployment and expanding in complex areas (with benefits expected to embed and build over time). ⁴³
• Improving claims accuracy and operational efficiency, as part of the operating impact from these capabilities. ¹

2) Key “one-time” framing: what will happen to the costs into 2027

Management’s core explanation was that the spending is incurred in 2026 and does not recur into 2027. ¹ They repeatedly stressed the intention: “one-time and non-recurring… will not go on beyond 2026 for these.” ⁵

They also quantified the EPS impact framing around below-the-line favorability and deployment timing:

• They referenced an approximately $0.75 of EPS tied to targeted investment spending included in the 2026 outlook from the first quarter. ⁶
• They further said they now expect to deploy approximately $0.80 of net below-the-line favorability into one-time accelerated investments in the second half, and that this $0.80 will not be recurring into 2027 (“not a recurring part… one-time for this year, not part of 2027”). ⁶

Additionally, management described these expenditures as part of a broader return-to-growth confidence framework: they expressed confidence in returning to at least 12% adjusted EPS earnings growth next year (i.e., 2027) and linked that confidence to the leverage from these enablers. ¹⁵

3) Expected operating payoff: when benefits show up and where they appear

Management stated that the investments take time to mature, with infrastructure and data expected to be put in place in 2026 and expecting to see results next year (2027). ⁴ They also said these investments should show up not only in the expense/cost structure but also in medical cost structure because they are aimed at medical management. ⁴

They characterized the operating mechanism as compressing cycle times and enabling faster interventions:

• Improving detection of cost pressures earlier and responding quickly with targeted action plans across clinical, network, payment integrity, and operating teams. ³
• Compressing “months of work into days” and using these capabilities to identify emerging cost drivers faster and deploy more focused interventions. ³

They also described concrete examples of capability areas tied to those investments:

• Member experience improvements through centralized/personalized engagement and proactive support. ¹³
• Medical cost management via analytics and AI-enabled tools to identify pressures earlier and implement clinical oversight and network/payment-integrity interventions. ¹
• Provider workflow improvements via Health OS, where deployed workflows were associated with “significant reduction” in avoidable denials, documentation requests, and administrative friction. ³

4) Management’s guidance-related stance: prudent expectations and “not in guidance as recurring”

While they were asked about how one-time spend affects growth rate/guidance, management’s consistent message was that the investment costs are not part of recurring earnings and are structured as a non-recurring opportunity to accelerate capabilities. ⁵¹

They also connected this prudently to confidence in next-year performance:

• They said the investments are “enabler of all of the key capabilities” and aimed at strengthening long-term performance through medical cost management and member/provider experience improvements. ¹
• They expressed confidence in the earnings growth path while emphasizing maturity timing and prudence (benefits build over time, not immediately, consistent with capability deployment). ⁴¹

Bottom line (direct answer)

Management said the “one-time, non-recurring” investments are 2026 spending designed to accelerate durable capabilities (technology and enablement tied to medical cost management, provider connectivity, and operational efficiency), with costs not recurring into 2027. ¹⁶⁵ They expect some benefits to be embedded/build over time, with the investment “data/infrastructure… this year” supporting results that they expect to see next year, particularly in the medical cost structure. ⁴